Was FDA Nit-Picking In Criticism Of Pfizer's EAGLES Trial?
When industry rep questioned whether problems with smoking cession drug trial were overestimated, FDA's rebuke was swift.
When industry rep questioned whether problems with smoking cession drug trial were overestimated, FDA's rebuke was swift.